These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32132421)

  • 41. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.
    Kumar N; Stowe ZN; Han X; Mancino MJ
    Am J Addict; 2016 Oct; 25(7):542-8. PubMed ID: 27629823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
    ESUB-MG Study Group
    BMC Fam Pract; 2016 Mar; 17():24. PubMed ID: 26931763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs.
    Suzuki J; Ellison TV; Connery HS; Surber C; Renner JA
    Acad Psychiatry; 2016 Jun; 40(3):498-502. PubMed ID: 26017618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of outcome after short-term stabilization with buprenorphine.
    Hillhouse M; Canamar CP; Ling W
    J Subst Abuse Treat; 2013 Mar; 44(3):336-42. PubMed ID: 23021099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.
    Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA
    Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials.
    Bergen AW; Baurley JW; Ervin CM; McMahan CS; Bible J; Stafford RS; Mudumbai SC; Saxon AJ
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409790
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 50. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
    Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
    Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
    Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
    Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
    Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
    Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.
    Soyka M; Strehle J; Rehm J; Bühringer G; Wittchen HU
    Eur Addict Res; 2017; 23(2):97-105. PubMed ID: 28376505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.
    Doorley SL; Ho CJ; Echeverria E; Preston C; Ngo H; Kamal A; Cunningham CO
    Subst Abus; 2017; 38(1):26-30. PubMed ID: 27897918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
    Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
    Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
    Lembke A; Ottestad E; Schmiesing C
    Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.